This patent protects a process of obtaining avian embryonic stem cells modified through homologous recombination to express recombinant proteins of interest. The new patent strengthens the company’s portfolio of patents in the area of avian stem cells.
Franck Grimaud, president of the board of directors, Vivalis, said: “This will allow the company to continue to strengthen its intellectual property portfolio and consolidate its position as world leader in the field of avian stem cells.”